Subsequent Breast Cancer Risk Higher for Child Cancer Survivors Receiving Doxorubicin
More than twofold increase in risk seen for those treated with ≥200 mg/m² cumulative doxorubicin versus no doxorubicin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.